Inclusion Criteria:

          -  Locally advanced/unresectable or metastatic disease

          -  Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version
             1.1 (RECIST v1.1)

          -  Eastern Cooperative Oncology Group Performance Status 0 to 1

          -  Life expectancy of >=12 weeks

          -  Consent to provide an archival tumor tissue sample

          -  Adequate cardiovascular, hematological, coagulative, hepatic and renal function

        Exclusion Criteria:

          -  Rapid disease progression or suspected hyperprogression or threat to vital organs or
             critical anatomical sites requiring urgent alternative medical intervention

          -  Untreated central nervous system (CNS) metastases

          -  Treated asymptomatic CNS metastases

          -  Spinal cord compression not definitively treated with surgery and/or radiation or
             previously diagnosed and treated spinal cord compression without evidence that disease
             has been clinically stable for >= 2 weeks before Cycle1 Day 1 (C1D1)

          -  Active or history of carcinomatous meningitis/leptomeningeal disease

          -  Uncontrolled tumor-related pain or symptomatic hypercalcemia

          -  Concurrent second malignancy

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results

          -  Episode of significant cardiovascular/cerebrovascular acute disease within 28 days
             before study treatment administration

          -  Active or uncontrolled infections

          -  Known HIV infection

          -  Hepatitis B virus (HBV) or hepatitis C virus infection

          -  Adverse events related to any prior radiotherapy, chemotherapy, targeted therapy, CPI
             therapy or surgical procedure must have resolved to Grade <=1, except alopecia Grade 2
             peripheral neuropathy, and hypothyroidism and/or hypopituitarism on a stable dosage of
             hormone replacement therapy

          -  Participants with bilateral pleural effusion

          -  Major surgery or significant traumatic injury < 28 days before study treatment
             administration or anticipation of the need for major surgery during study treatment

          -  Known allergy or hypersensitivity to any component of the formulations of the IMPs to
             be administered, including but not limited to hypersensitivity to Chinese hamster
             ovary cell products or other recombinant or humanized antibodies

          -  History of severe allergic anaphylactic reactions to chimeric, human or humanized
             antibodies, or fusion proteins

          -  Previous treatment with Interleukin-2 (IL-2)/Interleukin-5 (IL-15)-like cytokines.
             IL-2/IL-15 use as an adjunct treatment component for adoptive cell therapy is
             permitted.